Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cultured autologous oral mucosa epithelial sheet for bilateral limbal stem cell deficiency (FEMJA)
2024-513939-24-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cultured autologous oral mucosa epithelial sheet in bilateral limbal stem cell deficiency (LSCD), sponsored by Hospices Civils de Lyon. Planned start Sep 2024; status: authorised.
02
Drugs
cultured autologous oral mucosa epithelial sheet
03
Conditions
bilateral limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on 2024-513939-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513939-24-00.